{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T03:50:19Z","timestamp":1776829819175,"version":"3.51.2"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T00:00:00Z","timestamp":1776816000000},"content-version":"vor","delay-in-days":39,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"ACE-IMPACT Project, Covenant Applied Informatics and Communication Africa Centre of Excellence (CApIC-ACE), Covenant University, Nigeria."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15844-3","type":"journal-article","created":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T05:58:04Z","timestamp":1773467884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association of MET gene polymorphisms with breast cancer risk in Nigerian patients: a case\u2013control study"],"prefix":"10.1186","volume":"26","author":[{"given":"Doris Nnenna","family":"Amuji","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emeka E. J.","family":"Iweala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,14]]},"reference":[{"issue":"2","key":"15844_CR1","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1074\/jbc.RA119.011137","volume":"295","author":"J Aldahl","year":"2020","unstructured":"Aldahl J, Mi J, Pineda A, Kim WK, Olson A, Hooker E, et al. Aberrant activation of hepatocyte growth factor\/MET signaling promotes \u03b2-catenin\u2013mediated prostatic tumorigenesis. J Biol Chem. 2020;295(2):631\u201344. https:\/\/doi.org\/10.1074\/jbc.RA119.011137.","journal-title":"J Biol Chem"},{"key":"15844_CR2","doi-asserted-by":"publisher","unstructured":"Arif KMT, Elliott EK, Haupt LM, Griffiths LR. Regulatory mechanisms of epigenetic miRNA relationships in human cancer and potential as therapeutic targets. Cancers. 2020;12(10):2922. https:\/\/doi.org\/10.3390\/cancers12102922.","DOI":"10.3390\/cancers12102922"},{"key":"15844_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","volume":"66","author":"M Arnold","year":"2022","unstructured":"Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: global statistics for 2020 and 2040. Breast. 2022;66:15\u201323. https:\/\/doi.org\/10.1016\/j.breast.2022.08.010.","journal-title":"Breast"},{"issue":"23","key":"15844_CR4","doi-asserted-by":"publisher","first-page":"5963","DOI":"10.1158\/1078-0432.CCR-18-0876","volume":"24","author":"M Bahcall","year":"2018","unstructured":"Bahcall M, Awad MM, Sholl LM, Wilson FH, Xu M, et al. Amplification of wild-type KRAS imparts resistance to crizotinib in MET exon 14 mutant non\u2013small cell lung cancer. Clin Cancer Res. 2018;24(23):5963\u201376. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0876.","journal-title":"Clin Cancer Res"},{"key":"15844_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.lungcan.2018.09.008","volume":"125","author":"S Baldacci","year":"2018","unstructured":"Baldacci S, Kherrouche Z, Cockenpot V, Stoven L, Copin MC, Werkmeister E, et al. MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer. 2018;125:57\u201367. https:\/\/doi.org\/10.1016\/j.lungcan.2018.09.008.","journal-title":"Lung Cancer"},{"issue":"2","key":"15844_CR6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.4103\/IJPMMM.IJPMMM_9_25","volume":"1","author":"A Bansal","year":"2025","unstructured":"Bansal A, Dwivedi S, Dutta V. Current progress in gene therapy, gene editing, and targeted therapeutics for disease cure and clinical management: transformative advances of the past half-decade and beyond. Indian J Precis Med Mol Med. 2025;1(2):29\u201330. https:\/\/doi.org\/10.4103\/IJPMMM.IJPMMM_9_25.","journal-title":"Indian J Precis Med Mol Med"},{"issue":"12","key":"15844_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0333-9","volume":"31","author":"X Cao","year":"2014","unstructured":"Cao X, Hong X, Jia X, Zhang L, Chen G. Single-nucleotide polymorphism rs41736 located in MET was significantly associated with prognosis of small cell lung cancer patients. Med Oncol. 2014;31(12):333. https:\/\/doi.org\/10.1007\/s12032-014-0333-9.","journal-title":"Med Oncol"},{"issue":"6","key":"15844_CR8","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.clbc.2014.06.001","volume":"14","author":"D De Melo Gagliato","year":"2014","unstructured":"De Melo Gagliato D, Jardim DLF, Falchook G, Tang C, Zinner R, Wheler JJ, et al. Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson phase I unit. Clin Breast Cancer. 2014;14(6):468\u201374. https:\/\/doi.org\/10.1016\/j.clbc.2014.06.001.","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"15844_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01138-7","volume":"14","author":"LM Drusbosky","year":"2021","unstructured":"Drusbosky LM, Dawar R, Rodriguez E, Ikpeazu CV. Therapeutic strategies in METex14 skipping mutated non-small cell lung cancer. J Hematol Oncol. 2021;14(1):129. https:\/\/doi.org\/10.1186\/s13045-021-01138-7.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"15844_CR10","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.gendis.2018.05.001","volume":"5","author":"Y Feng","year":"2018","unstructured":"Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5(2):77\u2013106. https:\/\/doi.org\/10.1016\/j.gendis.2018.05.001.","journal-title":"Genes Dis"},{"key":"15844_CR11","doi-asserted-by":"publisher","unstructured":"Garay JP, Smith R, Devlin K, Hollern DP, Liby T, Liu M et al. Sensitivity to targeted therapy differs between HER2-amplified breast cancer cells harboring kinase and helical domain mutations in PIK3CA. Breast Cancer Res. 2021;23(1):81. https:\/\/doi.org\/10.1186\/s13058-021-01457-0.","DOI":"10.1186\/s13058-021-01457-0"},{"issue":"4","key":"15844_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2617","volume":"12","author":"S Gastaldi","year":"2010","unstructured":"Gastaldi S, Comoglio PM, Trusolino L. The Met oncogene and basal-like breast cancer: another culprit to watch out for? Breast Cancer Res. 2010;12(4):208. https:\/\/doi.org\/10.1186\/bcr2617.","journal-title":"Breast Cancer Res"},{"issue":"1","key":"15844_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-26967-5","volume":"12","author":"Y Gu","year":"2021","unstructured":"Gu Y, Chen Y, Wei L, Wu S, Shen K, et al. ABHD5 inhibits YAP-induced c-Met overexpression and colon cancer cell stemness via suppressing YAP methylation. Nat Commun. 2021;12(1):6711. https:\/\/doi.org\/10.1038\/s41467-021-26967-5.","journal-title":"Nat Commun"},{"key":"15844_CR14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01377","volume":"9","author":"C-Y Hu","year":"2019","unstructured":"Hu C-Y, Xu X-M, Hong B, Wu Z-G, Qian Y, Weng T-H, et al. Aberrant RON and MET co-overexpression as novel prognostic biomarkers of shortened patient survival and therapeutic targets of tyrosine kinase inhibitors in pancreatic cancer. Front Oncol. 2019;9:1377. https:\/\/doi.org\/10.3389\/fonc.2019.01377.","journal-title":"Front Oncol"},{"issue":"7","key":"15844_CR15","doi-asserted-by":"publisher","DOI":"10.3390\/jpm11070613","volume":"11","author":"C-S Huang","year":"2021","unstructured":"Huang C-S, Liu C-Y, Lu T-P, Huang C-J, Chiu J-H, Tseng L-M, et al. Targeted sequencing of Taiwanese breast cancer with risk stratification by the concurrent genes signature: a feasibility study. J Pers Med. 2021;11(7):613. https:\/\/doi.org\/10.3390\/jpm11070613.","journal-title":"J Pers Med"},{"key":"15844_CR16","doi-asserted-by":"publisher","unstructured":"Humphries B, Wang Z, Yang C. MicroRNA regulation of epigenetic modifiers in breast cancer. Cancers. 2019;11(7):897. https:\/\/doi.org\/10.3390\/cancers11070897.","DOI":"10.3390\/cancers11070897"},{"issue":"21","key":"15844_CR17","doi-asserted-by":"publisher","first-page":"27162","DOI":"10.1007\/s11356-021-12489-6","volume":"28","author":"VP Jayaseelan","year":"2021","unstructured":"Jayaseelan VP, Ramesh A, Arumugam P. Breast cancer and DDT: putative interactions, associated gene alterations, and molecular pathways. Environ Sci Pollut Res. 2021;28(21):27162\u201373. https:\/\/doi.org\/10.1007\/s11356-021-12489-6.","journal-title":"Environ Sci Pollut Res"},{"issue":"9","key":"15844_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091493","volume":"17","author":"M Ji","year":"2025","unstructured":"Ji M, Ganesan S, Xia B, Huo Y. Targeting c-MET alterations in cancer: a review of genetic drivers and therapeutic implications. Cancers. 2025;17(9):1493. https:\/\/doi.org\/10.3390\/cancers17091493.","journal-title":"Cancers"},{"key":"15844_CR19","doi-asserted-by":"publisher","first-page":"4195","DOI":"10.2147\/OTT.S189329","volume":"12","author":"D Kalapanida","year":"2019","unstructured":"Kalapanida D, Zagouri F, Gazouli M, Tsiakou A, Zografos E, Dimitrakakis C, et al. Evaluation of MET T1010I and MET rs40239 single-nucleotide polymorphisms in triple-negative breast cancer: a case\u2013control study. Onco Targets Ther. 2019;12:4195\u2013202. https:\/\/doi.org\/10.2147\/OTT.S189329.","journal-title":"Onco Targets Ther"},{"key":"15844_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2023\/9705159","volume":"2023","author":"FS Laskar","year":"2023","unstructured":"Laskar FS, Bappy MNI, Hossain MS, Alam Z, Afrin D, Saha S, et al. An in silico approach towards finding the cancer-causing mutations in human MET gene. Int J Genomics. 2023;2023:1\u201319. https:\/\/doi.org\/10.1155\/2023\/9705159.","journal-title":"Int J Genomics"},{"issue":"5","key":"15844_CR21","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.18632\/oncotarget.3094","volume":"6","author":"S Liu","year":"2015","unstructured":"Liu S, Meric-Bernstam F, Parinyanitikul N, Wang B, Eterovic AK, et al. Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015;6(5):2604\u201314. https:\/\/doi.org\/10.18632\/oncotarget.3094.","journal-title":"Oncotarget"},{"issue":"17","key":"15844_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174287","volume":"13","author":"S \u0141ukasiewicz","year":"2021","unstructured":"\u0141ukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanis\u0142awek A. Breast cancer\u2014epidemiology, risk factors, classification, prognostic markers, and current treatment strategies\u2014an updated review. Cancers. 2021;13(17):4287. https:\/\/doi.org\/10.3390\/cancers13174287.","journal-title":"Cancers"},{"issue":"52","key":"15844_CR23","doi-asserted-by":"publisher","first-page":"20123","DOI":"10.1074\/jbc.RA118.005395","volume":"293","author":"J Mi","year":"2018","unstructured":"Mi J, Hooker E, Balog S, Zeng H, Johnson DT, He Y, et al. Activation of hepatocyte growth factor\/MET signaling initiates oncogenic transformation and enhances tumor aggressiveness in the murine prostate. J Biol Chem. 2018;293(52):20123\u201336. https:\/\/doi.org\/10.1074\/jbc.RA118.005395.","journal-title":"J Biol Chem"},{"issue":"4","key":"15844_CR24","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/apm.13031","volume":"128","author":"S Mitra","year":"2020","unstructured":"Mitra S, Bal A, Kashyap D, Kumar S, Shrivastav S, Das A, et al. Tumour angiogenesis and c\u2010Met pathway activation \u2013 implications in breast cancer. APMIS. 2020;128(4):316\u201325. https:\/\/doi.org\/10.1111\/apm.13031.","journal-title":"APMIS"},{"issue":"1","key":"15844_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-020-01822-5","volume":"40","author":"C Modica","year":"2021","unstructured":"Modica C, Basilico C, Chiriaco C, Borrelli N, Comoglio PM, Vigna E. A receptor-antibody hybrid hampering MET-driven metastatic spread. J Exp Clin Cancer Res. 2021;40(1):32. https:\/\/doi.org\/10.1186\/s13046-020-01822-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"15844_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/405217","volume":"2015","author":"L Ning","year":"2015","unstructured":"Ning L, Yu Y, Liu X, Ai L, Zhang X, Rao W, et al. Association analysis of MET gene polymorphism with papillary thyroid carcinoma in a Chinese population. Int J Endocrinol. 2015;2015:1\u20135. https:\/\/doi.org\/10.1155\/2015\/405217.","journal-title":"Int J Endocrinol"},{"issue":"3","key":"15844_CR27","doi-asserted-by":"publisher","first-page":"603","DOI":"10.21037\/tlcr-19-339","volume":"9","author":"TR Overbeck","year":"2020","unstructured":"Overbeck TR, Cron DA, Schmitz K, Rittmeyer A, K\u00f6rber W, Hugo S, et al. Top-level MET gene copy number gain defines a subtype of poorly differentiated pulmonary adenocarcinomas with poor prognosis. Transl Lung Cancer Res. 2020;9(3):603\u201316. https:\/\/doi.org\/10.21037\/tlcr-19-339.","journal-title":"Transl Lung Cancer Res"},{"issue":"31","key":"15844_CR28","doi-asserted-by":"publisher","first-page":"12903","DOI":"10.1073\/pnas.0810402106","volume":"106","author":"MG Ponzo","year":"2009","unstructured":"Ponzo MG, Lesurf R, Petkiewicz S, O\u2019Malley FP, Pinnaduwage D, Andrulis IL, et al. Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A. 2009;106(31):12903\u20138. https:\/\/doi.org\/10.1073\/pnas.0810402106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"15844_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030271","volume":"11","author":"G Stella","year":"2019","unstructured":"Stella G, Corino A, Berzero G, Kolling S, Filippi A, Benvenuti S. Brain metastases from lung cancer: is MET an actionable target? Cancers. 2019;11(3):271. https:\/\/doi.org\/10.3390\/cancers11030271.","journal-title":"Cancers"},{"issue":"17","key":"15844_CR30","doi-asserted-by":"publisher","first-page":"29067","DOI":"10.18632\/oncotarget.16173","volume":"8","author":"Z-J Sun","year":"2017","unstructured":"Sun Z-J, Wu Y, Hou W-H, Wang Y-X, Yuan Q-Y, Wang H-J, et al. A novel bispecific c-MET\/PD-1 antibody with therapeutic potential in solid cancer. Oncotarget. 2017;8(17):29067\u201379. https:\/\/doi.org\/10.18632\/oncotarget.16173.","journal-title":"Oncotarget"},{"issue":"12","key":"15844_CR31","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1097\/FPC.0000000000000091","volume":"24","author":"Y Sunakawa","year":"2014","unstructured":"Sunakawa Y, Wakatsuki T, Yang D, Zhang W, Ning Y, Stintzing S, et al. Prognostic impact of c-MET polymorphism on clinical outcome in loco-regional gastric cancer patients. Pharmacogenet Genomics. 2014;24(12):588\u201396. https:\/\/doi.org\/10.1097\/FPC.0000000000000091.","journal-title":"Pharmacogenet Genomics"},{"issue":"1","key":"15844_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00238-4","volume":"7","author":"VYC Sung","year":"2021","unstructured":"Sung VYC, Knight JF, Johnson RM, Stern YE, Saleh SM, Savage P, et al. Co-dependency for MET and FGFR1 in basal triple-negative breast cancers. NPJ Breast Cancer. 2021;7(1):36. https:\/\/doi.org\/10.1038\/s41523-021-00238-4.","journal-title":"NPJ Breast Cancer"},{"issue":"4","key":"15844_CR33","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1158\/1078-0432.CCR-18-1640","volume":"25","author":"K Suzawa","year":"2019","unstructured":"Suzawa K, Offin M, Lu D, Kurzatkowski C, Vojnic M, Smith RS, et al. Activation of KRAS mediates resistance to targeted therapy in MET exon 14\u2013mutant non\u2013small cell lung cancer. Clin Cancer Res. 2019;25(4):1248\u201360. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-1640.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"15844_CR34","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/carcin\/bgn253","volume":"30","author":"S Tchatchou","year":"2009","unstructured":"Tchatchou S, Jung A, Hemminki K, Sutter C, Wappenschmidt B, Bugert P, et al. A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. Carcinogenesis. 2009;30(1):59\u201364. https:\/\/doi.org\/10.1093\/carcin\/bgn253.","journal-title":"Carcinogenesis"},{"issue":"48","key":"15844_CR35","doi-asserted-by":"publisher","first-page":"79365","DOI":"10.18632\/oncotarget.13033","volume":"7","author":"Q Wang","year":"2016","unstructured":"Wang Q, Yu X, Li Q, Qin L, Tan S, Zeng X, et al. Association between miR-199a rs74723057 and MET rs1621 polymorphisms and the risk of hepatocellular carcinoma. Oncotarget. 2016;7(48):79365\u201371. https:\/\/doi.org\/10.18632\/oncotarget.13033.","journal-title":"Oncotarget"},{"issue":"1130","key":"15844_CR36","doi-asserted-by":"publisher","DOI":"10.1259\/bjr.20211033","volume":"95","author":"L Wilkinson","year":"2022","unstructured":"Wilkinson L, Gathani T. Understanding breast cancer as a global health concern. Br J Radiol. 2022;95(1130):20211033. https:\/\/doi.org\/10.1259\/bjr.20211033.","journal-title":"Br J Radiol"},{"key":"15844_CR37","doi-asserted-by":"publisher","unstructured":"Zardavas D, Phillips WA, Loi S. PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. Breast Cancer Research. 2014;16(1):201. https:\/\/doi.org\/10.1186\/bcr3605.","DOI":"10.1186\/bcr3605"},{"issue":"22","key":"15844_CR38","doi-asserted-by":"publisher","first-page":"4238","DOI":"10.1242\/jcs.191684","volume":"129","author":"L Zhu","year":"2016","unstructured":"Zhu L, Xiong X, Kim Y, Okada N, Lu F, Zhang H, et al. Acid sphingomyelinase is required for cell surface presentation of Met receptor tyrosine kinase in cancer cells. J Cell Sci. 2016;129(22):4238\u201351. https:\/\/doi.org\/10.1242\/jcs.191684.","journal-title":"J Cell Sci"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15844-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15844-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T02:53:22Z","timestamp":1776826402000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15844-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,14]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15844"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15844-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,14]]},"assertion":[{"value":"18 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was reviewed and approved by the Covenant Health Research Ethics Committee (CHREC) of Covenant University, Nigeria.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"508"}}